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Abstract
Objective—Cervical cancer is the most common cancer among women in Malawi. National 
guidelines recommend screening women aged 30–45 years every five years; however, no specific 
recommendations exist for women with HIV. We aimed to assess the frequency of high-grade 
dysplasia (CIN 2 or CIN3) and cervical cancer among women in central Malawi and to examine 
associations with CIN2+ (CIN2/3 or cancer).
Methods—We extracted cervical pap smear, biopsy, loop electrosurgical excision procedure and 
uterine specimen reports from a hospital pathology database from November 2012 to November 
2013. We used logistic regression to estimate associations with CIN2+.
Results—We reviewed specimens from 824 women; we excluded 194 with unknown HIV status, 
leaving 630 in the analytic sample. Twelve percent had high-grade dysplasia and 109 women 
(17%) had cancer. Twenty-five percent of high-grade dysplasia cases and 35% of cancers occurred 
among women outside recommended screening ages. The odds of having CIN2+ were 6.55 times 
(95% CI 4.44–9.67) greater for HIV+ women.
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Conclusions—High-grade dysplasia and cervical cancer are very common among Malawian 
women, especially HIV+ women. HIV infection was strongly associated with CIN2+. Expanding 
screening to women not covered by current guidelines could avert a substantial proportion of 
cervical cancer cases in Malawi.
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Introduction
Cervical cancer is the second most common cancer and the leading cause of cancer death 
among women in Africa.1 Although incidence varies, many countries in sub-Saharan Africa 
have rates of cervical cancer which are among the highest in the world.2 In the Malawi 
national cancer registry, cervical cancer accounts for over 45% of female cancer cases.3 
More than 70% of Malawian women with cervical cancer are diagnosed with inoperable, 
advanced disease.4,5 In addition to high incidence of cervical cancer, Malawian women have 
one of the highest rates of cervical cancer mortality.6,7
Cervical cancer can be prevented by screening for and treating precancerous lesions. 
Cervical intraepithelial neoplasia (CIN) is a precancerous lesion that can progress to cervical 
cancer if left untreated. Progression to invasive cancer may require many years after the 
initial oncogenic human papillomavirus (HPV) infection, with low-grade cervical dysplasia 
(CIN1) progressing slowly and high-grade dysplasia (CIN2 or CIN3) progressing more 
rapidly to invasive cancer.8
Malawi implemented a visual inspection with acetic acid (VIA) screening campaign in 2004, 
to detect treatable precancerous lesions. Current reproductive health guidelines recommend 
screening women aged 30–45 years who are not pregnant, have no personal history of 
cervical cancer, have not undergone a total hysterectomy or have a sexually transmitted 
infection with abnormal discharge.9 However, a 2011 report from the Ministry of Health 
indicated that 12% of women with cervical cancer were between 20 and 29 years old, and 
32% were older than 50 years, suggesting that women outside the current VIA guidelines 
were interested in and might also benefit from screening.10
Additionally, Malawi has no specific recommendations for cervical cancer screening for 
women with HIV, even though HIV-infected women are at increased risk. Data from various 
settings demonstrate that HIV increases the risk of cervical cancer by 2–22 fold.11 This may 
reflect women with HIV having higher prevalence and persistence of co-infection with 
oncogenic HPV and also having diverse high-risk HPV types as previous studies have 
shown.12–15 HIV infection may also allow CIN to progress more rapidly to invasive 
cancer.16,17 As a result, specifically targeting HIV-positive women who are at high risk may 
be crucial for national cervical cancer prevention efforts in Malawi.
Approximately 11% of Malawi’s population is HIV-positive, and women account for 59% of 
HIV-infected individuals in the country.18 Understanding associations between HIV and 
cervical cancer in Malawi is therefore important for cancer control efforts as well as 
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comprehensive HIV care. Additionally, whether current VIA screening guidelines are 
adequate to avert most cervical cancer cases in Malawi is unknown. We therefore conducted 
a retrospective analysis of data from the Kamuzu Central Hospital (KCH) pathology 
laboratory database comparing pathologic diagnoses between women with and without HIV 
to assess associations between HIV status and high-grade cervical dysplasia and cancer.
Methods
Study population
KCH is one of the two national teaching hospitals in Malawi; KCH serves the entire central 
region with an estimated catchment area of five million people. The KCH pathology 
laboratory was initiated in July 2011 and has been previously described.19 Ongoing quality 
control procedures include weekly telepathology conferences with US collaborators using a 
virtual microscopy system.20 The laboratory provides services to all KCH departments and 
also processes specimens from other health facilities throughout the central region of 
Malawi. Specimens from seven health facilities were included in the study.
In Malawi, VIA screening is performed at district level health centres as well as public and 
private clinics. Women with positive VIA results and lesions amenable to cryotherapy may 
receive cryotherapy the same day if such services are available at that facility. Otherwise, 
women with positive results are referred to another facility for cryotherapy or further 
evaluation in the weekly colposcopy clinic conducted by consultant gynaecologists at KCH. 
Because our study relied on pathology laboratory data, the study population represents 
women who were likely VIA-positive, had a lesion not amenable to cryotherapy, or were 
clinically suspected to have cervical cancer, and were therefore referred for cervical biopsy. 
Cervical cytology was done for women whose repeat VIA was negative or colposcopy was 
normal at KCH colposcopy clinic. During the same appointment at the colposcopy clinic or 
after histological confirmation, abnormalities were treated with loop electrosurgical excision 
procedure (LEEP), cone biopsy or hysterectomy as needed.
Data
This cross-sectional analysis used electronic pathology reports from 1037 specimens from 
women undergoing cervical cytology, cervical biopsy, LEEP or hysterectomy for diagnostic 
evaluation or treatment of suspicious cervical lesions. We included all cervical, endometrial 
and uterine specimens collected from November 2012 to November 2013. The institutional 
pathology database was created for clinical purposes and does not include extensive data on 
patient demographics or risk factors for cervical cancer. Histology and cytology data as well 
as patient age and HIV status were extracted from pathology laboratory requisition forms.
Conventional cytology and colposcopy-directed biopsy services often resulted in multiple 
samples being submitted for the same women during diagnosis, treatment and follow-up. We 
conducted an individual patient-level analysis and only included one report per woman 
during the study period. For women with multiple specimens, we included the report with 
the most advanced diagnosis in the main analysis and also conducted sensitivity analysis 
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using the largest specimen received (i.e. pathology results based on a larger specimen may 
be more accurate than a cytology smear).
Permission to conduct this research was approved under the parent study approval covering 
the KCH cancer registry and pathology databases. The need for informed consent was 
exempted from the University of North Carolina-Chapel Hill institutional review board due 
to the nature of the study, which involved secondary analysis of routinely collected data.
Outcome variables
The diagnoses of CIN and cervical cancer were determined by a KCH pathologist. 
Histological and cytological results were categorised as no dysplasia/normal, CIN1, CIN2, 
CIN3 and invasive cancer. We defined high-grade dysplasia as CIN2 or CIN3 (CIN2/3). The 
main outcome in the logistic regression model was confirmed CIN2+, which included 
CIN2/3 and invasive cervical cancer.
Statistical approach
Patient and specimen characteristics were summarised descriptively to determine differences 
in proportions by HIV status. We compared the statistical significance of categorical 
variables using Chi-squared tests and t tests for age as a continuous variable. We estimated 
logistic regression models to assess the associations of HIV and age with CIN2+. We 
conducted two sensitivity analyses: (1) estimating models which included patients with 
unknown HIV status and (2) estimating results using the largest specimen for women with 
multiple laboratory reports. All statistical analyses were performed in STATA 12 using a 
two-sided alpha value of 0.05 to assess statistical significance.
Results
We extracted 1037 pathology reports from the KCH pathology database from patients 
undergoing pap test, cervical biopsy, LEEP or hysterectomy. We excluded reports with other 
diagnoses (e.g. leiomyoma and choriocarcinoma), inadequate specimens, conclusions 
without comments on dysplasia and those missing age. Details of the exclusion criteria are 
displayed in Figure 1.
Table 1 describes the results of 824 unique women after including only one report per 
woman. The mean age of women was 39.6 years (SD =12.0), and 20% of the sample was 
younger than the recommended starting age for screening (30 years). Of all women, 425 
(52%) were within the recommended age range for VIA screening (30–45 years). Histology 
specimens accounted for 62% of all samples, and 86% of specimens were from within KCH 
departments, such as the colposcopy clinic. HIV status was missing for 194 (23%) of 
reports.
For the main analysis, we excluded 194 women with no documented HIV status leaving 630 
women for the primary analytic sample. HIV prevalence among women with documented 
status was 36% (226/630). Among women with documented HIV status, 64% (403/630) had 
normal findings or no dysplasia, 6% (40) had CIN1, 12% (78) had CIN2/3 and 17% (109) 
had invasive cervical cancer. HIV-negative women more frequently had normal findings or 
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no dysplasia than HIV-positive women (79% vs. 37% respectively, p <0.001). Twenty-four 
per cent (55/226) of the HIV-positive women had CIN2/3 compared to 6% (23) of HIV-
negative women (p <0.001). Similarly, HIV-positive women were more likely to be 
diagnosed with cervical cancer (29% vs. 11%, p <0.001). HIV-positive women with cancer 
were significantly younger than HIV-negative women with cancer (38.4 vs. 49.1 years, p 
<0.001).
Figure 2 displays the frequency of cervical abnormalities and seroprevalence by age group. 
The majority of women with cancer were 35–39 years old, whereas the majority of women 
with CIN1 were younger than 30 years old. Although HIV prevalence was lower in older age 
groups, CIN2/3 and cervical cancer were still common. Thirty-five per cent (38/109) of 
women diagnosed with cancer were not within the recommended screening age group (30–
45 years). Thirty per cent of cancers were among women over 45 years old, and 5% of 
cervical cancers were diagnosed among women younger than 30 years old. High-grade 
dysplasia was also commonly diagnosed among women outside of the targeted screening 
ages; 14% of women with CIN2/3 were younger and 11% older than the recommended 
screening age range.
The results of logistic regression modeling on the outcome of CIN2+ are displayed in Table 
2. HIV significantly increased the likelihood of having CIN2+ (adjusted odds ratio [OR] 
6.55, 95%CI 4.43–9.67), after controlling for age. Similarly when controlling for HIV status, 
each additional year of age increased the odds of having CIN2+ by 4%. Adjusted ORs for 
HIV infection and age were not different in sensitivity analyses which included women with 
positive, negative and unknown HIV status (adjusted OR for HIV infection 6.41, 95%CI 
4.37–9.40 and adjusted OR for age 1.04 95%CI 1.02–1.05).
For additional sensitivity analyses, we analysed the largest sample instead of the highest 
grade conclusion among women with multiple specimens. Overall, 21 outcomes changed, 
such that there were fewer cases of CIN2/3 (79/824) and fewer cervical cancer cases 
(166/824). Over half of the women with different outcomes were HIV-positive (13/21) and 
four were indeterminate because they were undocumented and recorded as positive on a 
follow-up sample. Upon further examination of these women with different outcomes, eight 
uterine specimens were diagnosed with lower grade dysplasia than a previous biopsy, but 
were determined to be from cutting poor tissue sections. Nonetheless, using the largest 
specimen, we estimated similar associations with CIN2+ (adjusted OR for HIV infection 
6.16, 95%CI 4.14–9.14, adjusted OR for age 1.04, 95%CI 1.02–1.06).
Discussion
In this study of a pathology database at a national teaching hospital in Malawi, high-grade 
dysplasia and cervical cancer were common and were significantly associated with HIV 
infection and increasing age. The frequency of cervical cancer among all women with 
submitted gynecologic specimens was 17%, and notably, over 25% of high-grade dysplasia 
cases and 35% of cancer cases occurred among women outside currently recommended 
screening ages. Our sample consisted only of women with specimens submitted to the 
pathology laboratory, and also had a high HIV seroprevalence of 36%, more than three times 
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the generalised seroprevalence in Malawi of 11%. These factors likely explain the high 
frequency of cervical dysplasia and cancer in the study population.
We found that HIV infection was strongly associated with CIN2+ among Malawian women. 
The significant increase in high-grade dysplasia and cervical cancer among women with 
HIV is consistent with other studies.16 Similar to other reports from sub-Saharan Africa,17,21 
we found that HIV-positive women were diagnosed with cancer at younger ages, 
approximately a decade before HIV-negative women. This may suggest HIV-positive women 
are at risk of developing cancer at younger ages and have more rapid progression to cancer 
from the time of oncogenic HPV acquisition. However, this might also reflect differences in 
age structure between the HIV-positive and HIV-negative populations.22 Regardless, our data 
suggest that policy makers in Malawi should consider updating cervical cancer screening 
guidelines to expand screening for HIV-positive women. This may be particularly important 
to reduce morbidity and mortality from cervical cancer, given that more than half of new 
HIV infections occur among young Malawians aged 15–24 years who often have early 
sexual debut and engage in high-risk sex behaviours.23 For comparison, World Health 
Organization cervical cancer screening guidelines already recommend screening for women 
aged 30 years and older, and for all women or girls as soon as they have tested positive for 
HIV.24
We also found that older age was associated with CIN2+. Women older than 45 years were 
commonly diagnosed with cancer in this study. These women may have been diagnosed and 
treated at younger ages if screening was more widely implemented in Malawi thus 
preventing progression of pre-existing lesions. These data suggest that older women may 
also benefit from screening as cervical cancer prevention efforts continue to expand, and that 
potential cervical cancer cases can be averted by screening women older than current 
recommendations. A robust evidence base to guide screening policies for older women will 
become especially important in the coming decades, given the demographic transitions and 
aging of populations that are anticipated to occur with expanded access to anti-retroviral 
treatment (ART) in most sub-Saharan African countries including Malawi.
Similar to a 2011 Ministry of Health report, a large proportion of this sample diagnosed with 
cancer was outside of the recommended screening age range.10 This suggests the current 
screening guidelines are missing women at risk of developing cervical cancer. One-third of 
cancer cases occurred among women older than 45 years, who may not be encouraged to 
attend screening. Additionally 14% of women diagnosed with high-grade dysplasia were 
young women in their 20s, who potentially might benefit from decades of normal life 
expectancy if cervical cancer was effectively prevented. Given the continued high burden of 
cervical cancer and a decade of experience now with VIA screening in place in Malawi, 
identifying optimal strategies to increase screening coverage for women at risk is an urgent 
public health priority. Formal cost-effectiveness evaluations may help determine how 
broadly or narrowly VIA screening should be targeted under conditions of resource 
constraints, providing metrics that can be directly compared with other competing public 
health interventions.
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Our study has several strengths. This secondary analysis of routinely collected pathology 
data is highly reflective of clinical practice at a national teaching hospital in a resource-
limited country in sub-Saharan Africa. Additionally, we had pathologically confirmed 
diagnoses for all cases, which is notable in a region where the extreme scarcity of diagnostic 
pathology services has been frequently described.25 Our study included a variety of 
specimen types from women undergoing different screening and treatment procedures, with 
only 38% of specimens included being cytology. This is notable given that VIA rather than 
cytology has emerged as the principal mode for cervical cancer screening in many sub-
Saharan African settings, in part due to pathology limitations, and it may serve to make our 
study findings more generalisable to the region.
The main limitation of our study is the lack of access to extensive demographic or clinical 
data, including health and behavioural risk factors and presence of high-risk HPV types. For 
HIV-infected women, data regarding ART status and CD4 count were not available for 
analysis. Although we relied on provider reports of HIV status, it seems unlikely that a large 
proportion of women would have had HIV status mis-classified by their referring provider. 
Furthermore, findings were consistent when we included women with unknown HIV status 
in the analysis. Another important note is that the sample includes women referred to KCH 
for follow-up of abnormal screening, and the results may represent a subset of women at 
higher risk for unidentified reasons. Women were referred from various area health facilities 
(e.g. ART and sexually transmitted infection clinics) which see specific patient populations 
and use different screening procedures (e.g. screening younger women with risk factors or 
older symptomatic women). Finally, our data source was the institutional database for the 
main pathology laboratory serving the northern and central regions of Malawi. As such, 
there is referral bias in that only women who managed to have a hospital visit and had 
specimens submitted to the laboratory would have been included in our study. Results may 
therefore not reflect broader VIA screening programmes, where many women with normal 
VIA findings would never have subsequent specimens taken. In addition, biopsies were not 
always taken on women found to have advanced, inoperable cervical cancer on exam given 
that chemotherapy and radiation were not available treatment options during the study 
period.
In conclusion, we found that high-grade cervical dysplasia and cancer were very common 
among gynaecologic specimens submitted to a pathology laboratory at a national teaching 
hospital in Malawi, and these were significantly associated with HIV infection and 
increasing age. A substantial fraction of cases occurred outside the current age range 
recommended to receive cervical cancer screening in Malawi. These findings have 
significant implications for national cancer control efforts, given high morbidity and 
mortality which continue to result from cervical cancer in our setting. With VIA now well 
established in Malawi, strong consideration should be given to extend screening to HIV-
infected women and sexually active women outside currently recommended screening ages, 
including older women who may never have been screened. Opportunities to integrate HIV 
testing and cervical cancer screening could also be explored. Evidence-based expansion of 
cervical cancer screening that is informed by current and future research is needed to 
continue reducing burden from this common and often fatal disease, such that Malawian 
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women can reap benefits from cancer screening analogous to what has been achieved in 
resource-rich settings over the last many decades.
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Figure 1. 
Inclusion and exclusion criteria applied to identify the analytic sample.
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Figure 2. 
Frequency of cervical abnormalities among women with documented HIV status (n =630).
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Table 2
Estimation results from logistic regression modela.
CIN2+b Adjusted OR 95% CI
HIV-positive 6.55*** 4.44–9.67
Age 1.04*** 1.02–1.06
Observations 630
a
Includes only women with documented HIV status.
bCIN2/3 or cervical cancer
CIN: cervical intraepithelial neoplasia; OR: odds ratio; CI: confidence interval.
***p <0.001.
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